1
|
Czepielewski MA, Garret Q, Vencio SAC, Rassi N, Faria MS, Senn CCP, Bronstein MD, Cerqueira MJAG, Neves ACL, Spinola-Castro AM, Cunha MPR, Leite NR, Wassermann GE, Alegria MC, Toffoletto O, Afiune J, Baradelli R, Rodrigues DG, Scharf M. Switching from originator recombinant growth hormone (Genotropin™) to biosimilar (CRISCY™): Results from a 6-month, multicentric, non-inferiority, extension trial. Growth Horm IGF Res 2021; 56:101372. [PMID: 33260063 DOI: 10.1016/j.ghir.2020.101372] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/20/2020] [Revised: 09/14/2020] [Accepted: 11/15/2020] [Indexed: 11/27/2022]
Abstract
OBJECTIVE A previous 12-month comparative trial with Criscy™ (r-hGH Cristália), a biosimilar recombinant growth hormone, demonstrated equivalent efficacy and safety to Genotropin™. This extension trial evaluated the effects of switching patients treated with Genotropin™ to the biosimilar Criscy™ over an additional 6-month treatment period, comparing efficacy, safety, and immunogenicity parameters with patients remaining in the Criscy™ arm. DESIGN This extension study included 11 research centers and 81 patients who participated in the CERES study (Czepielewski et al., 2019 [1]). Participants from the Genotropin™ arm (n = 39) had the drug replaced by Criscy™ and the remaining participants were kept in the Criscy™ arm (n = 42) for an additional 6-month period to evaluate immunogenicity, efficacy (growth rate, height SDS), and safety (laboratory tests, and adverse events). RESULTS Before the switch, both Criscy™ and Genotropin groups were similar concerning demographics, and auxological measures: age, sex, height, height SDS, weight, and BMI. Height velocity (HV) after 18 months of treatment was 8.7 ± 1.56 cm/year for Criscy™ group and 8.9 ± 1.36 cm/year for Genotropin™ group in the ITT population (p = 0.43). The auxological parameters and IGF-1 and IGFBP-3 SDS were comparable between both groups of patients. No participants were excluded from the study due to adverse events. There were no clinical or statistical relevant differences between the treatment groups concerning frequency, distribution, intensity, and AEs outcome. Similarly, no new anti-r-hGH (ADA) cases among patients that switched from Genotropin™ to Criscy™ were reported. No neutralizing antibody (nAb) was detected in either group. CONCLUSIONS This trial showed that switching from originator recombinant human growth hormone to Criscy™ had no impact on efficacy, safety, nor immunogenicity as compared to continued treatment with Criscy™. Growth rates and ADA incidence remained the same as seen before the switch.
Collapse
Affiliation(s)
- M A Czepielewski
- Serviço de Endocrinologia, Hospital de Clínicas de Porto Alegre, UFRGS, Porto Alegre, RS, Brazil.
| | | | - S A C Vencio
- ICF - Instituto de Ciências Farmacêuticas de Estudos e Pesquisas Ltda, Aparecida de Goiânia, GO, Brazil
| | - N Rassi
- Hospital Alberto Rassi - HGG, Goiânia, GO, Brazil
| | - M S Faria
- Hospital Universitário da Universidade Federal do Maranhão/HU/UFMA, São Luis, MA, Brazil
| | - C C P Senn
- Centro de Diabetes de Curitiba, Curitiba, PR, Brazil
| | - M D Bronstein
- CPQUALI Pesquisa Clínica Ltda, São Paulo, SP, Brazil
| | - M J A G Cerqueira
- Instituto de Ensino e Pesquisa Clínica do Ceará, Fortaleza, CE, Brazil
| | - A C L Neves
- Instituto de Medicina Integral Professor Fernando Figueira - IMIP, Recife, PE, Brazil
| | | | - M P R Cunha
- CAEP - Centro Avançado de Estudos e Pesquisas Ltda, Campinas, SP, Brazil
| | - N R Leite
- Cristália Produtos Químicos Farmacêuticos Ltda, Itapira, SP, Brazil
| | - G E Wassermann
- Cristália Produtos Químicos Farmacêuticos Ltda, Itapira, SP, Brazil
| | - M C Alegria
- Cristália Produtos Químicos Farmacêuticos Ltda, Itapira, SP, Brazil
| | - O Toffoletto
- Cristália Produtos Químicos Farmacêuticos Ltda, Itapira, SP, Brazil
| | - J Afiune
- Cristália Produtos Químicos Farmacêuticos Ltda, Itapira, SP, Brazil
| | - R Baradelli
- Cristália Produtos Químicos Farmacêuticos Ltda, Itapira, SP, Brazil
| | - D G Rodrigues
- Cristália Produtos Químicos Farmacêuticos Ltda, Itapira, SP, Brazil
| | - M Scharf
- Centro de Diabetes de Curitiba, Curitiba, PR, Brazil
| |
Collapse
|
2
|
Dang J, Barker P, Baumert A, Bentvelzen M, Berkman E, Buchholz N, Buczny J, Chen Z, De Cristofaro V, de Vries L, Dewitte S, Giacomantonio M, Gong R, Homan M, Imhoff R, Ismail I, Jia L, Kubiak T, Lange F, Li DY, Livingston J, Ludwig R, Panno A, Pearman J, Rassi N, Schiöth HB, Schmitt M, Sevincer AT, Shi J, Stamos A, Tan YC, Wenzel M, Zerhouni O, Zhang LW, Zhang YJ, Zinkernagel A. A Multilab Replication of the Ego Depletion Effect. Soc Psychol Personal Sci 2021; 12:14-24. [PMID: 34113424 DOI: 10.1177/1948550619887702] [Citation(s) in RCA: 44] [Impact Index Per Article: 14.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
There is an active debate regarding whether the ego depletion effect is real. A recent preregistered experiment with the Stroop task as the depleting task and the antisaccade task as the outcome task found a medium-level effect size. In the current research, we conducted a preregistered multilab replication of that experiment. Data from 12 labs across the globe (N = 1,775) revealed a small and significant ego depletion effect, d = 0.10. After excluding participants who might have responded randomly during the outcome task, the effect size increased to d = 0.16. By adding an informative, unbiased data point to the literature, our findings contribute to clarifying the existence, size, and generality of ego depletion.
Collapse
Affiliation(s)
- Junhua Dang
- Department of Neuroscience, Uppsala University, Sweden
| | - Paul Barker
- Social Cognition Center Cologne, University of Cologne, Germany
| | - Anna Baumert
- Max Planck Institute for Research on Collective Goods, Bonn, Germany.,TUM School of Education, München, Germany
| | | | - Elliot Berkman
- Department of Psychology, University of Oregon, Eugene, OR, USA
| | - Nita Buchholz
- Department of Psychology, University of Koblenz-Landau, Mainz, Germany
| | - Jacek Buczny
- Department of Experimental and Applied Psychology, VU University Amsterdam, the Netherlands
| | - Zhansheng Chen
- Department of Psychology, The University of Hong Kong, Hong Kong
| | - Valeria De Cristofaro
- Department of Social and Developmental Psychology, University of Rome "Sapienza," Italy
| | - Lianne de Vries
- Department of Experimental and Applied Psychology, VU University Amsterdam, the Netherlands
| | | | - Mauro Giacomantonio
- Department of Social and Developmental Psychology, University of Rome "Sapienza," Italy
| | - Ran Gong
- Department of Psychology, Beijing Sport University, China
| | - Maaike Homan
- Amsterdam Institute for Social Science Research, University of Amsterdam, the Netherlands
| | - Roland Imhoff
- Social and Legal Psychology, Johannes Gutenberg University Mainz, Germany
| | - Ismaharif Ismail
- Department of Psychology, National University of Singapore, Singapore
| | - Lile Jia
- Department of Psychology, National University of Singapore, Singapore
| | - Thomas Kubiak
- Heath Psychology, Johannes Gutenberg University Mainz, Germany
| | | | - Dan-Yang Li
- Department of Psychology, Beijing Sport University, China
| | | | - Rita Ludwig
- Department of Psychology, University of Oregon, Eugene, OR, USA
| | - Angelo Panno
- Department of Social and Developmental Psychology, University of Rome "Sapienza," Italy
| | - Joshua Pearman
- Department of Psychology, University of Oregon, Eugene, OR, USA
| | - Niklas Rassi
- Institute of Psychology, University of Hamburg, Germany
| | | | - Manfred Schmitt
- Department of Psychology, University of Koblenz-Landau, Mainz, Germany
| | | | - Jiaxin Shi
- Department of Psychology, The University of Hong Kong, Hong Kong
| | | | - Yia-Chin Tan
- Department of Psychology, National University of Singapore, Singapore
| | - Mario Wenzel
- Heath Psychology, Johannes Gutenberg University Mainz, Germany
| | - Oulmann Zerhouni
- Laboratoire Parisien de Psychologie Sociale, University Paris Nanterre, France
| | - Li-Wei Zhang
- Department of Psychology, Beijing Sport University, China
| | - Yi-Jia Zhang
- Department of Psychology, Beijing Sport University, China
| | - Axel Zinkernagel
- Department of Psychology, University of Koblenz-Landau, Mainz, Germany
| |
Collapse
|
3
|
Czepielewski MA, Garret Q, Vencio SAC, Rassi N, Felicio JS, Faria MS, Senn CCP, Bronstein MD, Cerqueira MJAG, Neves ACL, Sgarbi JA, Spinola-Castro AM, Cunha MPR, Bandeira F, Toffoletto O, Afiune J, Baradelli R, Rodrigues DG, Scharf M. Efficacy and safety of a biosimilar recombinant human growth hormone (r-hGH Cristalia) compared with reference r-hGH in children with growth hormone deficiency (CERES study): A randomized, multicentric, investigator-blind, phase 3 trial. Growth Horm IGF Res 2019; 48-49:29-35. [PMID: 31493626 DOI: 10.1016/j.ghir.2019.07.003] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/26/2019] [Revised: 07/28/2019] [Accepted: 07/30/2019] [Indexed: 10/26/2022]
Abstract
OBJECTIVE The CERES study was a randomized, multicenter, investigator-blind trial aimed to evaluate the efficacy and safety of a recombinant human growth hormone (r-hGH) developed by Cristalia, as a biosimilar product, with analytical, functional and pharmacokinetics similarities comparable to Genotropin™, in children with growth hormone deficiency (GHD). DESIGN A total of 135 naïve prepubertal children with GHD were recruited, of whom 97 were randomized in 14 Brazilian sites to received either r-hGH Cristalia (n = 49) or Genotropin™ (n = 48). Efficacy was evaluated considering the height standard deviation score (SDS) and growth velocity as auxological parameters, IGF-1 and IGFBP-3 were measured as pharmacodynamic parameters during 12 months treatment time. Safety was assessed by monitoring adverse events, immunogenicity, blood count with platelets, biochemical profile and hormonal levels particularly fasting glucose, insulin and HbA1C. RESULTS The auxological parameters and IGF-1 and IGFBP-3 levels were comparable between both groups of patients. At end of study or the 12th month treatment, the means growth velocity was 9.7 cm/year and 9.5 cm/year, for r-hGH Cristalia and Genotropin™, respectively. The ANCOVA mean difference between the groups was 0.16 cm/year to Cristalia group (CI 95% = -0.72 to 1.03 cm/year). There was no difference in adherence among the treatment groups. The safety profile was comparable between groups. CONCLUSIONS The clinical similarity between r-hGH and Genotropin™ was demonstrated within 12 month of treatment. On the basis of comparability of quality, safety, and efficacy to the reference product, r-hGH from Cristalia can be considered a cost-effective therapeutic option for patients with growth disorders.
Collapse
Affiliation(s)
- M A Czepielewski
- Serviço de Endocrinologia, Hospital de Clínicas de Porto Alegre, UFRGS, Porto Alegre, RS, Brazil.
| | | | - S A C Vencio
- ICF - Instituto de Ciências Farmacêuticas de Estudos e Pesquisas Ltda, Aparecida de Goiânia, GO, Brazil
| | - N Rassi
- Hospital Alberto Rassi - HGG, Goiânia, GO, Brazil
| | - J S Felicio
- Hospital Universitário João de Barros Barreto, Universidade Federal do Pará, Belém, PA, Brazil
| | - M S Faria
- Hospital Universitário da Universidade Federal do Maranhão/HU/UFMA, São Luis, MA, Brazil
| | - C C P Senn
- Centro de Diabetes de Curitiba, Curitiba, PR, Brazil
| | - M D Bronstein
- CPQUALI Pesquisa Clínica Ltda, São Paulo, SP, Brazil
| | - M J A G Cerqueira
- Instituto de Ensino e Pesquisa Clínica do Ceará, Fortaleza, CE, Brazil
| | - A C L Neves
- Instituto de Medicina Integral Professor Fernando Figueira - IMIP, Recife, PE, Brazil
| | - J A Sgarbi
- Unidade de Pesquisa Clínica de Marília Ltda (UpCliM), Marília, SP, Brazil
| | | | - M P R Cunha
- CAEP - Centro Avançado de Estudos e Pesquisas Ltda, Campinas, SP, Brazil
| | - F Bandeira
- Centro de Pesquisas Médicas Básica e Clínica Ltda, Recife, PE, Brazil
| | - O Toffoletto
- Cristália Produtos Químicos Farmacêuticos Ltda, Itapira, SP, Brazil
| | - J Afiune
- Cristália Produtos Químicos Farmacêuticos Ltda, Itapira, SP, Brazil
| | - R Baradelli
- Cristália Produtos Químicos Farmacêuticos Ltda, Itapira, SP, Brazil
| | - D G Rodrigues
- Cristália Produtos Químicos Farmacêuticos Ltda, Itapira, SP, Brazil
| | - M Scharf
- Centro de Diabetes de Curitiba, Curitiba, PR, Brazil
| |
Collapse
|
4
|
DePaula AL, Macedo ALV, Rassi N, Machado CA, Schraibman V, Silva LQ, Halpern A. Laparoscopic treatment of type 2 diabetes mellitus for patients with a body mass index less than 35. Surg Endosc 2008; 22:706-16. [PMID: 17704886 DOI: 10.1007/s00464-007-9472-9] [Citation(s) in RCA: 127] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
BACKGROUND Type 2 diabetes mellitus (T2DM) is a common disease with numerous complications. Bariatric surgery is an efficient procedure for controlling T2DM in morbidly obese patients. In T2DM, the incretin effect is either greatly impaired or absent. This study aimed to evaluate the preliminary results from interposing a segment of ileum into the proximal jejunum associated with a sleeve or diverted sleeve gastrectomy to control T2DM in patients with a body mass index (BMI) less than 35 kg/m(2). METHODS For this study, 39 patients (16 women and 23 men) underwent two laparoscopic procedures comprising different combinations of ileal interposition into the proximal jejunum via a sleeve or diverted sleeve gastrectomy. The mean age of these patients was 50.3 years (range, 36-66 years). The mean BMI was 30.1 kg/m(2) (range, 23.4-34.9 kg/m(2)). All the patients had a diagnosis of T2DM that had persisted for at least 3 years and evidence of stable treatment with oral hypoglycemic agents or insulin for at least 12 months. The mean duration of T2DM was 9.3 years (range, 3-22 years). RESULTS The mean operative time was 185 min, and the median hospital stay was 4.3 days. Four major complications occurred in the short term (30-days), and the mortality rate was 2.6%. The mean postoperative follow-up period was 7 months (range, 4-16 months), and the mean percentage of weight loss was 22%. The mean postoperative BMI was 24.9 kg/m(2) (range, 18.9-31.7 kg/m(2)). An adequate glycemic control was achieved for 86.9% of the patients, and 13.1% had important improvement. The patients whose glycemia was not normalized were using a single oral hypoglycemic agent. No patient needed insulin therapy postoperatively. All the patients except experienced normalization of their cholesterol levels. Targeted triglycerides levels were achieved by 71% of the patients, and hypertension was controlled for 95.8%. CONCLUSIONS The laparoscopic ileal interposition via either a sleeve gastrectomy or diverted sleeve gastrectomy seems to be a promising procedure for the control of T2DM and the metabolic syndrome. A longer follow-up period is needed.
Collapse
Affiliation(s)
- A L DePaula
- Department of Surgery, Hospital de Especialidades, Goiânia, Brazil.
| | | | | | | | | | | | | |
Collapse
|
5
|
DePaula AL, Macedo ALV, Rassi N, Vencio S, Machado CA, Mota BR, Silva LQ, Halpern A, Schraibman V. Laparoscopic treatment of metabolic syndrome in patients with type 2 diabetes mellitus. Surg Endosc 2008; 22:2670-8. [PMID: 18347866 DOI: 10.1007/s00464-008-9808-0] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2007] [Revised: 01/11/2008] [Accepted: 01/24/2008] [Indexed: 02/06/2023]
Abstract
BACKGROUND Metabolic syndrome refers to risk factors for cardiovascular disease. Hyperglycemia is a critical component contributing to the predictive power of the syndrome. This study aimed to evaluate the results from the laparoscopic interposition of an ileum segment into the proximal jejunum for the treatment of metabolic syndrome in patients with type 2 diabetes mellitus and a body mass index (BMI) lower than 35. METHODS Laparoscopic procedures were performed for 60 patients (24 women and 36 men) with a mean age of 51.7 +/- 6.4 years (range, 27-66 years) and a mean BMI of 30.1 +/- 2.7 (range, 23.6-34.4). All the patients had a diagnosis of type 2 diabetes mellitus (T2DM) given at least 3 years previously and evidence of stable treatment using oral hypoglycemic agents, insulin, or both for at least 12 months. The mean duration of type 2 diabetes mellitus was 9.6 +/- 4.6 years (range, 3-22 years). Metabolic syndrome was diagnosed for all 60 patients. Arterial hypertension was diagnosed for 70% of the patients (mean number of drugs, 1.6) and hypertriglyceridemia for 70%. High-density lipoprotein was altered in 51.7% of the patients and the abdominal circumference in 68.3%. Two techniques were performed: ileal interposition (II) into the proximal jejunum and sleeve gastrectomy (II-SG) or ileal interposition associated with a diverted sleeve gastrectomy (II-DSG). RESULTS The II-SG procedure was performed for 32 patients and the II-DSG procedure for 28 patients. The mean postoperative follow-up period was 7.4 months (range, 3-19 months). The mean BMI was 23.8 +/- 4.1 kg/m(2), and 52 patients (86.7%) achieved adequate glycemic control. Hypertriglyceridemia was normalized for 81.7% of the patients. An high-density lipoprotein level higher than 40 for the men and higher than 50 for the women was achieved by 90.3% of the patients. The abdominal circumference reached was less than 102 cm for the men and 88 cm for the women. Arterial hypertension was controlled in 90.5% of the patients. For the control of metabolic syndrome, II-DSG was the more effective procedure. CONCLUSIONS Laparoscopic II-SG and II-DSG seem to be promising procedures for the control of the metabolic syndrome and type 2 diabetes mellitus. A longer follow-up period is needed.
Collapse
|
6
|
Abstract
The BB rat has a marked T cell lymphocytopenia, with a near absence of peripheral "helper" T cells recognized by monoclonal antibody W3/25 (W3/25+ T cells). The lymphocytes of the BB rat's spleen and thymus were examined for the presence of W3/25+ T cells, which were found to be absent in the spleen but present in normal amounts in the thymus. Concanavalin A (Con A) responsiveness was absent in the BB's peripheral blood and spleen but present in the thymus. Thus, in these three lymphoid compartments, Con A responsiveness directly correlated with the presence or absence of W3/25+ T cells. These lymphocyte abnormalities in the BB rat are notably different from lymphocyte changes present in human type I diabetes.
Collapse
|
7
|
Abstract
Approximately 50% of Wistar "BB" rats spontaneously develop overt diabetes mellitus characterized by loss of beta-cells and "insulitis." To define abnormalities of immunoregulation in these rats, we quantitated their major circulating lymphocyte subsets. Independent of the development of diabetes, we found the BB rats to have a markedly increased percentage of circulating B lymphocytes which is secondary to a severe T-cell lymphocytes which is secondary to a severe T-cell lymphocytopenia, with the major circulating T-cell subset reacting with monoclonal antibody W3/25 markedly decreased. This lymphocytopenia is present in every animal studied and contrasted with studies of the nondiabetic Wistar strain from which the "BB" rats were developed.
Collapse
|